Latest On Genmab A/S (GNMSF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-10 23:19 EST | News | Genmab A/S (GMAB) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-04-17 15:43 EST | News | Argenx, Genmab in pact to study antibody therapies for immunology and oncology | N/A | |
| 2023-02-23 09:01 EST | News | Genmab A/S GAAP EPS of DKK83.65, revenue of DKK14.6B; initiates FY23 outlook | N/A | |
| 2023-02-22 20:27 EST | News | Genmab A/S (GMAB) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-02-06 12:00 EST | News | AbbVie pins hopes on newer drugs and deals to face Humira knockoffs – WSJ | N/A | |
| 2022-11-16 04:42 EST | News | Genmab A/S 2022 Q3 - Results - Earnings Call Presentation | N/A | |
| 2022-11-09 16:34 EST | News | Genmab A/S (GMAB) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-08-11 03:03 EST | News | Genmab A/S (GMAB) CEO Jan van de Winkel on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-12 08:11 EST | News | Genmab A/S (GMAB) CEO Jan van de Winkel on Q1 2022 Results - Earning Call Transcript | N/A | |
| 2022-05-12 08:11 EST | News | Genmab A/S 2022 Q1 - Results - Earnings Call Presentation | N/A | |
| 2022-02-17 07:08 EST | News | Genmab A/S (GMAB) CEO Jan van de Winkel on Q4 2021 Results - Earning Calls Transcript | N/A | |
| 2022-02-17 07:08 EST | News | Genmab A/S 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-11-10 20:38 EST | News | Genmab A/S 2021 Q3 - Results - Earnings Call Presentation | N/A | |
| 2021-11-10 20:38 EST | News | Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-18 01:05 EST | News | Genmab: Monoclonal Antibody Experts, Low Risk Business Model | N/A | |
| 2021-08-12 08:12 EST | News | Genmab A/S 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-08-12 08:12 EST | News | Genmab A/S (GMAB) CEO Jan van de Winkel on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-05-06 03:31 EST | News | Genmab A/S (GMAB) CEO Jan van de Winkel on Q1 2021 Results - Earnings Call Transcript | N/A | |
| 2021-03-18 23:29 EST | Analyst Rating | The Analyst Target Price has increased from $400.12 to $402.86. | Buy | |
| 2021-03-17 22:34 EST | Analyst Rating | The Analyst Target Price has decreased from $401.77 to $400.12. | Neutral | |
| 2021-03-16 22:52 EST | Analyst Rating | The Analyst Target Price has decreased from $402.81 to $401.77. | Neutral | |
| 2021-03-13 05:05 EST | Analyst Rating | The Analyst Target Price has increased from $400.87 to $402.81. | Buy | |
| 2021-03-12 13:04 EST | Analyst Rating | The Analyst Target Price has increased from $0 to $400.87. | Buy | |
| 2021-02-27 05:34 EST | News | Genmab A/S 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-02-25 16:01 EST | Earnings Estimate | An EPS average of $0.67 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2021-02-25 16:01 EST | Earnings Estimate | An EPS average of $0.65 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-02-25 16:01 EST | Earnings Estimate | An EPS average of $8.81 is estimated for the 2022 year. | Buy | |
| 2021-02-25 05:44 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-24 00:41 EST | News | Genmab A/S (GMAB) CEO Jan van de Winkel on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-26 22:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-10 01:16 EST | News | Genmab A/S 2020 Q3 - Results - Earnings Call Presentation | N/A | |
| 2020-11-08 01:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-06 05:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-05 21:30 EST | News | Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-09-26 15:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 07:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 07:42 EST | News | Genmab A/S 2020 Q2 - Results - Earnings Call Presentation | N/A | |
| 2020-08-14 02:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-13 05:48 EST | News | Genmab A/S (GMAB) CEO Jan van de Winkel on Q2 2020 Results - Earnings Call Transcript | N/A | |
| 2020-08-06 14:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 18:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 06:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 22:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 14:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 19:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 10:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 18:38 EST | Financials | Company financials have been released. | Neutral | |
About Genmab A/S (GNMSF):
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and BioNTech, Janssen, Novo Nordisk A/S, and BliNK Biomedical SAS. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
General
- Name Genmab A/S
- Symbol GNMSF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 781
- Fiscal Year EndDecember
- Web URLhttp://www.genmab.com
Valuation
- Trailing PE 92.98
- Forward PE 80.65
- Price/Sales (Trailing 12 Mt.) 13.8
- Price/Book (Most Recent Quarter) 7.25
- Enterprise Value Revenue 1.89
- Enterprise Value EBITDA 3.1
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $4.27
- Next Year EPS Estimate $7.73
- Profit Margin 47%
- Return on Assets 22%
- Return on Equity 29%
- Earnings Per Share $3.59
- Revenue Per Share $0
- Gross Profit 10.11 billion
- Quarterly Earnings Growth -31%
Highlights
- Market Capitalization 21.27 billion
- PEG Ratio 8.94
- Analyst Target Price $402.86
- Book Value Per Share $18.00
Share Statistics
- Shares Outstanding 65.44 million
- Shares Float 64.68 million
- % Held by Insiders 464%
- % Held by Institutions 46.88%
Technicals
- Beta 0.54
- 52 Week High $456.83
- 52 Week Low $173.79
- 50 Day Moving Average 369.84
- 200 Day Moving Average 378.12
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
ESG Rating
Genmab A/S (GNMSF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Genmab A/S (GNMSF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $2.04 billion | $1.41 | $1.29 | 9.3% |
| 2020-09-30 | 2020-12-31 | $N/A | $1.44 | ||
| 2020-06-30 | 2020-09-30 | $5.45 billion | $1.27 | ||
| 2020-03-31 | 2020-06-30 | $N/A | $7.74 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $444.43 million | $0.60 | $24.80 | -97.56% |
| 2019-09-30 | 2019-12-31 | $151.81 million | $3.36 | $3.76 | -10.7% |
| 2019-06-30 | 2019-09-30 | $117.02 million | $1.21 | $1.58 | -23.49% |
| 2019-03-31 | 2019-06-30 | $88.77 million | $0.21 | $1.41 | -85.41% |
| 2018-12-31 | 2019-03-31 | $189.8 million | $0.18 | $8.58 | -97.95% |
| 2018-09-30 | 2018-12-31 | $92.95 million | $2.06 | $3.60 | -42.75% |
| 2018-06-30 | 2018-09-30 | $79.61 million | $0.45 | $2.46 | -81.71% |
| 2018-03-31 | 2018-06-30 | $112.47 million | $0.66 | $5.60 | -88.22% |
| 2017-12-31 | 2018-03-31 | $164.13 million | $0.53 | $8.04 | -93.42% |
| 2017-09-30 | 2017-12-31 | $50.99 million | $2.03 | $1.98 | 2.77% |
| 2017-06-30 | 2017-09-30 | $118.83 million | -$0.01 | $7.37 | -100.19% |
| 2017-03-31 | 2017-06-30 | $250.78 million | $0.76 | ||
| 2016-12-31 | 2017-03-31 | $927.46 million | $0.04 | $6.81 | -99.45% |
| 2016-09-30 | 2016-12-31 | $1.93 | $0.77 | 150% | |
| 2016-06-30 | 2016-09-30 | $0.46 | $1.59 | -70.96% | |
| 2016-03-31 | 2016-06-30 | $0.41 | -$0.36 | 212.78% | |
| 2015-12-31 | 2016-03-31 | -$0.03 | $5.96 | -100.49% | |
| 2015-09-30 | 2015-12-31 | $0.95 | $0.97 | -1.74% | |
| 2015-06-30 | 2015-09-30 | $0.34 | $2.05 | -83.22% | |
| 2015-03-31 | 2015-06-30 | $0.04 | $3.95 | -98.98% | |
| 2014-12-31 | 2015-03-31 | $0.52 | $0.62 | -15.56% | |
| 2014-09-30 | 2014-12-31 | $0.19 | $1.35 | -85.65% | |
| 2014-06-30 | 2014-09-30 | $0.47 | $0.32 | 47.28% | |
| 2014-03-31 | 2014-06-30 | -$0.08 | -$0.06 | -40.83% | |
| 2013-12-31 | 2014-03-31 | $0.32 | $0.17 | 91.06% | |
| 2013-09-30 | 2013-12-31 | $0.21 | |||
| 2013-06-30 | 2013-09-30 | $0.02 | |||
| 2013-03-31 | 2013-06-30 | -$0.09 | |||
| 2012-12-31 | 2013-03-31 | $0.10 | |||
| 2012-09-30 | 2012-12-31 | -$0.06 | |||
| 2012-06-30 | 2012-09-30 | -$0.17 | |||
| 2012-03-31 | 2012-06-30 | $0.03 | |||
| 2011-12-31 | 2012-03-31 | -$0.25 | |||
| 2011-09-30 | 2011-12-31 | -$0.13 | |||
| 2011-06-30 | 2011-09-30 | -$0.03 | |||
| 2011-03-31 | 2011-06-30 | -$0.31 | |||
| 2010-12-31 | 2011-03-31 | -$0.43 | |||
| 2010-09-30 | 2010-12-31 | -$0.31 | |||
| 2010-06-30 | 2010-06-30 | -$0.34 | |||
| 2010-03-31 | 2010-03-31 | -$0.54 | |||
| 2009-12-31 | 2009-12-31 | -$1.57 | |||
| 2009-09-30 | 2009-09-30 | -$0.38 | |||
| 2009-06-30 | 2009-06-30 | -$0.47 | |||
| 2009-03-31 | 2009-03-31 | -$0.78 | |||
| 2008-12-31 | 2008-12-31 | -$1.74 | |||
| 2008-09-30 | 2008-09-30 | -$0.16 | |||
| 2008-06-30 | 2008-06-30 | -$1.32 | |||
| 2008-03-31 | 2008-03-31 | -$0.95 | |||
| 2007-12-31 | 2007-12-31 | -$0.54 | |||
| 2007-09-30 | 2007-09-30 | -$0.72 | |||
| 2007-06-30 | 2007-06-30 | -$0.04 | |||
| 2007-03-31 | 2007-03-31 | -$0.32 |
Genmab A/S (GNMSF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 926 million | N/A | 775 million | N/A | 100.35 million |
| Income Before Tax | 551 million | N/A | 4.33 billion | N/A | 293.44 million |
| Selling General Administrative | 231 million | N/A | 179 million | N/A | 17.49 million |
| Gross Profit | N/A | N/A | N/A | N/A | 444.43 million |
| Ebit | -128 million | N/A | 4.54 billion | N/A | 326.58 million |
| Operating Income | 887 million | N/A | 4.5 billion | N/A | 326.58 million |
| Income Tax Expense | N/A | 141 million | N/A | 85 million | 72.54 million |
| Total Revenue | 2.04 billion | N/A | 5.45 billion | N/A | 444.43 million |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -33.15 million |
| Net Income From Continuing Operations | 581 million | N/A | 3.38 billion | N/A | 220.9 million |
| Net Income Applicable to Common Shares | N/A | 530 million | N/A | 269 million | 220.9 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | 919 million | N/A | -168.37 million | 48468.57 |
| Change to Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | -1.64 billion | N/A | 9 million | -172.7 million | -6.75 million |
| Net Borrowings | -30 million | N/A | -8 million | -1.42 million | -1.05 million |
| Total Cash Flow from Financial Activities | N/A | 4 million | N/A | 1.1 million | 530.97 million |
| Change to Operating Activities | 1.49 billion | N/A | 2.1 billion | -267.89 million | -19.41 million |
| Change in Cash | N/A | 884 million | N/A | -163.76 million | 592.74 million |
| Total Cash from Operating Activities | 7.23 billion | -39 million | 2.19 billion | 26.25 million | 46.58 million |
| Depreciation | N/A | N/A | N/A | -3.1 million | 1.01 million |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | -450097.55 | -34.31 million |
| Change to Net Income | 5.21 billion | N/A | -179 million | 76.35 million | -13.42 million |
| Capital Expenditures | N/A | 145 million | N/A | 3.04 million | 3.38 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 2.02 billion | N/A | 2.81 billion | N/A | 164.49 million |
| Total Stockholder Equity | 19.12 billion | N/A | 17.87 billion | N/A | 2.11 billion |
| Other Current Liabilities | N/A | 2.22 billion | N/A | N/A | 136.88 million |
| Total Assets | 21.14 billion | N/A | 20.68 billion | N/A | 2.27 billion |
| Common Stock | N/A | 65 million | N/A | 65 million | 9.76 million |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | 7.11 billion | 6.46 billion | 5.88 billion | 2.43 billion | 319.68 million |
| Other Liabilities | N/A | 492 million | N/A | 17 million | 450247.64 |
| Other Assets | N/A | 256 million | N/A | 131 million | 22.51 million |
| Cash | 7.26 billion | N/A | 6.61 billion | N/A | 533.09 million |
| Total Current Liabilities | 1.25 billion | 2.26 billion | 2.01 billion | N/A | 140.78 million |
| Other Stockholder Equity | N/A | 74 million | N/A | 107 million | 14.71 million |
| Property, Plant & Equipment | N/A | 730 million | N/A | 491 million | 62.13 million |
| Total Current Assets | 18.79 billion | 19.5 billion | 19.14 billion | N/A | 2.1 billion |
| Long Term Investments | 1.08 billion | N/A | 152 million | N/A | 22.36 million |
| Net Tangible Assets | N/A | 18.09 billion | N/A | 13.96 billion | 2.04 billion |
| Short Term Investments | 8.82 billion | N/A | 6.18 billion | N/A | 1.11 billion |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A |
Genmab A/S (GNMSF) Chart:
Genmab A/S (GNMSF) News:
Below you will find a list of latest news for Genmab A/S (GNMSF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Genmab A/S (GNMSF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Genmab A/S (GNMSF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|